Tandem Diabetes Care (TNDM) Stock Overview
Designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
TNDM Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Tandem Diabetes Care, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.82 |
| 52 Week High | US$29.65 |
| 52 Week Low | US$9.98 |
| Beta | 1.64 |
| 1 Month Change | -37.80% |
| 3 Month Change | -31.95% |
| 1 Year Change | -43.60% |
| 3 Year Change | -56.75% |
| 5 Year Change | -84.92% |
| Change since IPO | -93.34% |
Recent News & Updates
Narrative Update • May 07
TNDM: Pharmacy Model Transition Will Drive More Predictable Margins Over Time
The analyst price target for Tandem Diabetes Care has been nudged higher to $31.19 from $30.76 as analysts factor in slightly stronger revenue growth assumptions, a lower discount rate, and a modestly higher future P/E, following a series of research updates pointing to benefits from the pharmacy model, international expansion, and new product momentum. Analyst Commentary Recent Street research on Tandem Diabetes Care clusters around the same key themes you are seeing in the revised price target, with most analysts focused on the pharmacy model, international expansion, and new product execution, while also flagging areas where the story still needs to prove itself.Narrative Update • Apr 23
TNDM: Pharmacy Channel Shift Will Drive More Predictable Margins And Upside
The updated analyst price target for Tandem Diabetes Care moves from $28.91 to $30.76. This reflects analysts' focus on the pharmacy channel transition, international direct distribution, product momentum such as the Mobi pump, and expectations for more predictable growth and improving margins.
Narrative Update • Apr 07
TNDM: Pharmacy And PayGo Shift Will Support More Predictable Cash Flow
Narrative Update: Tandem Diabetes Care The analyst price target for Tandem Diabetes Care has shifted higher to approximately $50.59 from $49.38. Analysts cite updated views on pharmacy channel economics, international direct market potential and margin trajectory, along with a lower future P/E assumption, as key factors behind the revised outlook.Recent updates
Narrative Update • May 07
TNDM: Pharmacy Model Transition Will Drive More Predictable Margins Over Time
The analyst price target for Tandem Diabetes Care has been nudged higher to $31.19 from $30.76 as analysts factor in slightly stronger revenue growth assumptions, a lower discount rate, and a modestly higher future P/E, following a series of research updates pointing to benefits from the pharmacy model, international expansion, and new product momentum. Analyst Commentary Recent Street research on Tandem Diabetes Care clusters around the same key themes you are seeing in the revised price target, with most analysts focused on the pharmacy model, international expansion, and new product execution, while also flagging areas where the story still needs to prove itself.Narrative Update • Apr 23
TNDM: Pharmacy Channel Shift Will Drive More Predictable Margins And Upside
The updated analyst price target for Tandem Diabetes Care moves from $28.91 to $30.76. This reflects analysts' focus on the pharmacy channel transition, international direct distribution, product momentum such as the Mobi pump, and expectations for more predictable growth and improving margins.Narrative Update • Apr 07
TNDM: Pharmacy And PayGo Shift Will Support More Predictable Cash Flow
Narrative Update: Tandem Diabetes Care The analyst price target for Tandem Diabetes Care has shifted higher to approximately $50.59 from $49.38. Analysts cite updated views on pharmacy channel economics, international direct market potential and margin trajectory, along with a lower future P/E assumption, as key factors behind the revised outlook.
Narrative Update • Mar 24
TNDM: Pharmacy And PayGo Transition Will Sustain Overvaluation Risk Beyond 2026
Narrative Update The analyst fair value estimate for Tandem Diabetes Care has been raised from $14.00 to $20.00. This change reflects analysts' updated models that factor in pharmacy channel traction, the PayGo transition, new product uptake, and a wider range of higher Street price targets.Narrative Update • Mar 10
TNDM: Pharmacy And PayGo Transition Will Drive More Predictable Cash Flow
Analysts have lifted their fair value estimate for Tandem Diabetes Care to $49.38 from $44.42, reflecting updated revenue and margin assumptions tied to the shift toward a pharmacy and pay as you go model that many expect could support stronger long term growth and cash flow. Analyst Commentary Recent Street research points to a clear shift in sentiment around Tandem Diabetes Care as analysts rework their models to reflect the pharmacy and pay as you go transition.Narrative Update • Feb 24
TNDM: PayGo Pharmacy Transition Will Shape Predictable Margins And Execution Risks
Analysts have lifted their fair value estimate for Tandem Diabetes Care to $28.91 from $25.71, citing stronger pharmacy channel traction, improving pump shipments, and expectations for more predictable growth and margins under the evolving PayGo and pharmacy-centric model. Analyst Commentary Bullish and cautious voices are both active on Tandem Diabetes Care, and recent research updates focus heavily on how the pharmacy and PayGo model could influence the company’s growth profile, margins, and cash generation, as well as how quickly that shows up in results.Seeking Alpha • Feb 23
Tandem Diabetes Care: Strong Q4 Execution Amid A PayGo Transition
Summary Tandem Diabetes Care, Inc. delivered strong Q4 '25 results, with revenue and gross margin beats driving a 32% stock surge. TNDM’s shift to a pay-as-you-go model will temporarily compress reported revenue but should enable smoother, recurring income and improved long-term economics. International expansion and direct sales transitions are expected to drive 9–10% growth abroad, despite temporary $15M headwinds from distributor destocking. Valuation remains attractive at 1.63x TTM P/S, with product differentiation and algorithmic automation underpinning long-term upside despite near-term earnings pressure. Read the full article on Seeking AlphaNarrative Update • Feb 09
TNDM: Sector Sentiment Shift Will Sustain Overvaluation Risk Into 2026
Analysts have lifted their price targets on Tandem Diabetes Care by roughly US$4 to around US$25, citing a shift in broader healthcare sector sentiment and expectations that stock performance could better align with company fundamentals heading into 2026. Analyst Commentary Recent research updates cluster around a US$25 price target for Tandem Diabetes Care, but the tone is not uniformly optimistic.Narrative Update • Jan 26
TNDM: Organic Growth Repricing Thesis Will Rely On Pump Pipeline Execution
Analysts have raised their average price expectations for Tandem Diabetes to about US$25.71. Recent target increases into the US$16 to US$25 range are supported by views that more stable healthcare policy and a closer link between organic growth and valuations could help reset how the stock is priced.Narrative Update • Jan 11
TNDM: Future Pump Market Competition And Product Pipeline Will Drive Repricing
Analysts have nudged their price target for Tandem Diabetes Care to about $25.70 from roughly $24.80. This reflects updated views on revenue growth assumptions, profit margins and future P/E expectations, informed by a series of recent target increases from major research firms.Narrative Update • Dec 26
TNDM: Future Pump Market Competition Will Shape Risk And Opportunity Balance
Analysts have lifted their price targets on Tandem Diabetes Care, supporting a fair value increase from about $20.64 to $24.81 per share. They highlight improving revenue growth expectations, stronger projected profit margins, and a modestly lower risk profile, while still maintaining generally neutral ratings on the stock.Narrative Update • Dec 12
TNDM Cautious Outlook Will Persist Despite Rising Street Optimism
Analysts have raised their fair value estimate for Tandem Diabetes Care to $14.00 from $11.00. A series of higher price targets from major firms, along with improving growth and margin expectations, supports a modestly lower discount rate and a higher future earnings multiple.Narrative Update • Nov 02
TNDM: Revenue Momentum And Renewal Cycle Will Fuel Continued Upside Potential
Analysts have modestly reduced their price target for Tandem Diabetes Care to $20.64 from $21.05 per share. They cite heightened competitive pressure and tempered profit margin expectations, despite signs of steady revenue growth.Analysis Article • Oct 29
Market Might Still Lack Some Conviction On Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Even After 26% Share Price Boost
Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ) shareholders are no doubt pleased to see that the share price has bounced...Narrative Update • Oct 18
Pharmacy Channel And Europe Expansion Will Build Future Advantage
The analyst price target for Tandem Diabetes Care has increased modestly, rising by approximately $0.29 to $21.05. Analysts cite healthier revenue and margin expectations, ongoing product launches, and potential policy tailwinds supporting the company's near-term outlook.Narrative Update • Oct 04
Pharmacy Channel And Europe Expansion Will Build Future Advantage
Analysts have lowered their price target for Tandem Diabetes Care from approximately $22.62 to $20.76. They cite tempered expectations for growth and profitability due to increased U.S. competition and ongoing commercial transformation.Analysis Article • Aug 26
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Could Be 50% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for Tandem Diabetes Care is US$24.21 based on 2 Stage Free Cash Flow to Equity...Narrative Update • Aug 08
Pharmacy Channel And Europe Expansion Will Build Future Advantage
Tandem Diabetes Care’s consensus price target has been revised downward as a result of a lower future P/E despite improved net profit margin, with the fair value estimate decreasing from $27.90 to $24.05. What's in the News Tandem Diabetes Care announced a voluntary medical device correction for select t:slim X2 insulin pumps due to a speaker-related issue that can result in a discontinuation of insulin delivery, leading to 700 confirmed adverse events and 59 reported injuries (Key Developments, 2025-08-07).Analysis Article • Jul 16
Lacklustre Performance Is Driving Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) 27% Price Drop
Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ) shares have had a horrible month, losing 27% after a relatively good period...Analysis Article • Jun 26
Tandem Diabetes Care (NASDAQ:TNDM) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • May 15
Shareholders May Be More Conservative With Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) CEO Compensation For Now
Key Insights Tandem Diabetes Care will host its Annual General Meeting on 21st of May Salary of US$732.0k is part of...Analysis Article • May 03
Earnings Release: Here's Why Analysts Cut Their Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Price Target To US$35.52
Shareholders of Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ) will be pleased this week, given that the stock price is up...
New Narrative • Mar 22
FDA Approval Of Control-IQ+ Will Expand Market Reach In Type 2 Diabetes
Operational improvements and new tech launches are expected to boost customer adoption and revenue, with increased market presence and margin expansion initiatives in Europe.Analysis Article • Feb 28
Not Many Are Piling Into Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stock Yet As It Plummets 40%
Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ) shareholders won't be pleased to see that the share price has had a very...Seeking Alpha • Feb 27
Tandem Diabetes Q4 Earnings Review: I Don't Share The Market's Skepticism
Summary Tandem Diabetes Care, Inc. released its Q4 and full-year 2024 earnings after the bell yesterday, and the market has given the stock the thumbs down. Shares are down >30% in trading today, despite a beat on revenues of $940m, and on EPS, with a return to positive cash flow. Guidance for 2025 is for revenues of ~$1bn — the growth rate does not seem to have impressed Wall Street, and Q4 underperformance issues also played a part. Nevertheless, Tandem's business looks robust to me, with plenty of opportunities for growth and profitability. The T2D market, going “direct” outside the US, the new Mobi device and a target of 25% operating margin long-term all offer hope that Tandem stock can rise again, as it has in the past, defying expectations. Read the full article on Seeking AlphaAnalysis Article • Jan 18
Is There An Opportunity With Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) 47% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Tandem Diabetes Care fair value estimate is US$66.45 Current...Analysis Article • Dec 27
Is Tandem Diabetes Care (NASDAQ:TNDM) Weighed On By Its Debt Load?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Seeking Alpha • Nov 28
Tandem Diabetes: Recurring Value Erosion, Not Right Point In Cycle To Own
Summary Tandem's sales growth has failed to translate to shareholder wealth for several reasons. Free cash flow per share has significantly decreased from over $1.50/share in 2022 to less than $0.70/share, reflecting a $1/share reduction. Investors now value a dollar of invested capital in this business far lower than 2 years ago. Read the full article on Seeking AlphaAnalysis Article • Nov 16
Slammed 27% Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Screens Well Here But There Might Be A Catch
To the annoyance of some shareholders, Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ) shares are down a considerable 27% in...Analysis Article • Sep 28
Health Check: How Prudently Does Tandem Diabetes Care (NASDAQ:TNDM) Use Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Aug 31
Potential Upside For Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Not Without Risk
There wouldn't be many who think Tandem Diabetes Care, Inc.'s ( NASDAQ:TNDM ) price-to-sales (or "P/S") ratio of 3.6x...Seeking Alpha • Aug 14
Tandem Diabetes: Mobi's Surprise Sales Fail To Offset Flat Operating Margin
Summary Tandem Diabetes Care shares have repriced since my last publication with improving fundamentals. But continued cash flow divergence, inefficient cash deployment, and low business returns marred Q2 earnings. The intrinsic worth of the business is around $37-$40 per share today under base case assumptions shown here. Read the full article on Seeking AlphaAnalysis Article • Aug 04
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
A week ago, Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ) came out with a strong set of second-quarter numbers that could...Analysis Article • Jul 12
Is It Time To Consider Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM)?
While Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ) might not have the largest market cap around , it received a lot of...Analysis Article • Jun 18
Is Tandem Diabetes Care (NASDAQ:TNDM) Weighed On By Its Debt Load?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • May 29
Tandem Diabetes Care: Recent Rally Fully Deserved, Likely More Upside Here
Summary Tandem Diabetes Care is a company that specializes in diabetes management products, most notably insulin pumps for T1D patients. TNDM stock has been performing well, with a 100% increase in value over the past year. Shares traded at >$150 per share in 2021, before a torrid bear run dragged it to <$15. Fears that the company could not compete with market rivals or new market entrants were overblown, and the company has recovered admirably from multiple setbacks. Management hopes to reach 1m customers and drive a 25% operating margin - that is a long way off, but the recent bull run can continue on improving performance and industry dynamics. Read the full article on Seeking AlphaAnalysis Article • May 10
Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) 26% Jump Shows Its Popularity With Investors
Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ) shares have continued their recent momentum with a 26% gain in the last...Analysis Article • May 04
A Look At The Fair Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Tandem Diabetes Care fair value estimate is US$50.08 With...Analysis Article • Mar 26
At US$30.10, Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Worth Looking At Closely?
While Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ) might not have the largest market cap around , it led the NASDAQGM...Analysis Article • Mar 08
Even With A 27% Surge, Cautious Investors Are Not Rewarding Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Performance Completely
Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ) shareholders have had their patience rewarded with a 27% share price jump in...Analysis Article • Feb 22
Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Jan 14
Estimating The Intrinsic Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Tandem Diabetes Care fair value estimate is US$31.68 Tandem...Analysis Article • Dec 27
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stock Rockets 63% But Many Are Still Ignoring The Company
Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ) shareholders would be excited to see that the share price has had a great...Analysis Article • Nov 12
Is It Too Late To Consider Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM)?
Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ), might not be a large cap stock, but it received a lot of attention from a...Analysis Article • Oct 06
Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Intrinsic Value Is Potentially 53% Above Its Share Price
Key Insights Tandem Diabetes Care's estimated fair value is US$29.80 based on 2 Stage Free Cash Flow to Equity Current...Analysis Article • Sep 17
Does Tandem Diabetes Care (NASDAQ:TNDM) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Aug 08
Should You Think About Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Now?
Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ), might not be a large cap stock, but it saw a significant share price rise...Shareholder Returns
| TNDM | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -13.2% | 0.08% | -0.3% |
| 1Y | -43.6% | -24.4% | 24.1% |
Return vs Industry: TNDM underperformed the US Medical Equipment industry which returned -24.4% over the past year.
Return vs Market: TNDM underperformed the US Market which returned 24.1% over the past year.
Price Volatility
| TNDM volatility | |
|---|---|
| TNDM Average Weekly Movement | 14.5% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TNDM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TNDM's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 2,500 | John Sheridan | www.tandemdiabetes.com |
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It’s flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user’s body.
Tandem Diabetes Care, Inc. Fundamentals Summary
| TNDM fundamental statistics | |
|---|---|
| Market cap | US$878.54m |
| Earnings (TTM) | -US$94.55m |
| Revenue (TTM) | US$1.03b |
0.9x
P/S Ratio-9.3x
P/E RatioIs TNDM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TNDM income statement (TTM) | |
|---|---|
| Revenue | US$1.03b |
| Cost of Revenue | US$463.14m |
| Gross Profit | US$564.40m |
| Other Expenses | US$658.94m |
| Earnings | -US$94.55m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.38 |
| Gross Margin | 54.93% |
| Net Profit Margin | -9.20% |
| Debt/Equity Ratio | 454.5% |
How did TNDM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/18 15:40 |
| End of Day Share Price | 2026/05/15 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tandem Diabetes Care, Inc. is covered by 42 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Johnson | Baird |
| Matthew Miksic | Barclays |
| Bruce Jackson | Benchmark Company |